QIAGEN NV Stock
-
Your prediction
QIAGEN NV Stock
Pros and Cons of QIAGEN NV in the next few years
Pros
Cons
Performance of QIAGEN NV vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| QIAGEN NV | - | - | - | - | - | - | - |
| Uniqure B.V. | 8.340% | 17.425% | 8.664% | 122.780% | -17.434% | -29.009% | -60.716% |
| Novocure Ltd | 4.340% | 0.465% | -33.525% | -40.103% | -65.907% | -88.146% | -84.483% |
| Ironwood Pharmaceuticals | 12.200% | 35.294% | 46.032% | -75.916% | -78.095% | -91.962% | -89.302% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When evaluating the financials of QIAGEN (US symbol: QGEN) in the Biotechnology & Medical Research industry, various metrics come to light that provide a clearer picture of the company's performance and financial health. Overall, QIAGEN presents a mixed bag of strengths and weaknesses. On one hand, the company showcases robust revenue generation and a stable EBITDA, while on the other hand, there are certain red flags that investors should acknowledge.
Pros of QIAGEN's Financials
Steady Growth in Revenue: At $1.94 billion in revenue for the trailing twelve months (TTM), QIAGEN demonstrates a significant ability to generate sales. Despite a slight decline in quarterly revenue growth year-over-year (down by 5.5%), the company has managed to maintain a solid revenue stream indicative of a well-established customer base and product demand in their field.
Comments
